Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)’s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $4.80 and last traded at $4.76, with a volume of 3373 shares trading hands. The stock had previously closed at $4.61.

The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 3.66.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last posted its earnings results on Tuesday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.03). Imprimis Pharmaceuticals had a negative net margin of 28.59% and a negative return on equity of 372.57%. The company had revenue of $10.74 million during the quarter.

In other Imprimis Pharmaceuticals news, Director Robert J. Kammer sold 10,000 shares of Imprimis Pharmaceuticals stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $4.21, for a total value of $42,100.00. Following the transaction, the director now owns 899,827 shares in the company, valued at $3,788,271.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 30,000 shares of company stock worth $102,100 in the last quarter. 13.78% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp grew its stake in Imprimis Pharmaceuticals by 145.8% in the first quarter. Northern Trust Corp now owns 67,013 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 39,750 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Imprimis Pharmaceuticals in the third quarter valued at about $259,000. Ardsley Advisory Partners grew its stake in Imprimis Pharmaceuticals by 42.9% in the second quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $220,000 after purchasing an additional 30,000 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Imprimis Pharmaceuticals by 104.3% in the third quarter. JPMorgan Chase & Co. now owns 117,990 shares of the specialty pharmaceutical company’s stock worth $328,000 after acquiring an additional 60,248 shares in the last quarter. Finally, Granite Investment Partners LLC boosted its holdings in Imprimis Pharmaceuticals by 153.8% in the second quarter. Granite Investment Partners LLC now owns 170,962 shares of the specialty pharmaceutical company’s stock worth $376,000 after acquiring an additional 103,607 shares in the last quarter. Institutional investors own 8.65% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Imprimis Pharmaceuticals (IMMY) Hits New 52-Week High at $4.80” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://theolympiareport.com/2018/11/15/imprimis-pharmaceuticals-immy-hits-new-52-week-high-at-4-80.html.

Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.

Recommended Story: What is the quiet period?

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.